No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
Actimmune |
Interferon gamma-1b |
D00747 |
2件: IFNGR1, IFNGR2 |
19件: Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Salmonella infection, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis |
1件: 326 |
2 |
Actimmune registry |
- |
- |
- |
- |
1件: 326 |
3 |
Ap1903 |
Ap1903 |
- |
- |
- |
3件: 60, 285, 326 |
4 |
Bpx-501 t cells |
- |
- |
- |
- |
4件: 65, 284, 285, 326 |
5 |
Busulfan |
Busulfan |
D00248 |
- |
- |
13件: 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326 |
6 |
Busulfan, cyclophosphamide, thymoglobulin, fludarabine (conditioning regimen) |
Cyclophosphamide |
D00287, D07760 |
- |
- |
1件: 326 |
7 |
Calcitriol |
Calcitriol |
D00129 |
1件: VDR |
4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis |
8件: 37, 46, 49, 66, 96, 158, 235, 326 |
8 |
Cald hr-d (high-risk, regimen c) |
- |
- |
- |
- |
4件: 19, 20, 234, 326 |
9 |
Cald hr-d (high-risk, regimen d) |
- |
- |
- |
- |
4件: 19, 20, 234, 326 |
10 |
Cald sr-a (standard-risk, regimen a) |
- |
- |
- |
- |
4件: 19, 20, 234, 326 |
11 |
Cald sr-b (standard-risk, regimen b) |
- |
- |
- |
- |
4件: 19, 20, 234, 326 |
12 |
Campath, busulfan, clofarabine |
Clofarabine |
D03546 |
3件: POLA1, POLA2, RRM1 |
6件: DNA replication, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
1件: 326 |
13 |
Campath-1h |
Alemtuzumab |
D02802 |
- |
- |
6件: 19, 20, 60, 234, 285, 326 |
14 |
Cd34+ enriched, t cell depleted donor stem cell product |
- |
- |
- |
- |
1件: 326 |
15 |
Clofarabine |
Clofarabine |
D03546 |
3件: POLA1, POLA2, RRM1 |
6件: DNA replication, Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
9件: 19, 20, 40, 46, 49, 60, 96, 234, 326 |
16 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
43件: 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
17 |
Cyclophosphamide 30 |
Cyclophosphamide |
D00287, D07760 |
- |
- |
3件: 65, 285, 326 |
18 |
Cyclophosphamide 40 |
Cyclophosphamide |
D00287, D07760 |
- |
- |
3件: 65, 285, 326 |
19 |
Cyclosporin |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
16件: 14, 38, 39, 49, 53, 56, 60, 62, 63, 97, 113, 164, 222, 223, 274, 326 |
20 |
Cyclosporin, methotrexate (gvhd prophylaxis) |
Methotrexate |
D00142, D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
1件: 326 |
21 |
Fludarabine |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
17件: 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 326 |
22 |
Fludarabine monophosphate |
Fludarabine |
D01907, D07966 |
1件: RRM1 |
5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism |
4件: 49, 65, 284, 326 |
23 |
Hematopoetic stem cell transplantation |
- |
- |
- |
- |
5件: 19, 65, 120, 160, 326 |
24 |
Imd preparative regimen |
- |
- |
- |
- |
4件: 19, 20, 234, 326 |
25 |
Interferon gamma |
- |
- |
- |
- |
2件: 65, 326 |
26 |
Interferon gamma-1b |
- |
- |
- |
- |
7件: 65, 85, 90, 228, 299, 301, 326 |
27 |
Methotrexate |
Methotrexate |
D00142, D02115 |
2件: DHFR, DHFR2 |
4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
33件: 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
28 |
Osteopetrosis haploidentical only preparative regimen |
- |
- |
- |
- |
4件: 19, 20, 234, 326 |
29 |
Osteopetrosis only preparative regimen |
- |
- |
- |
- |
4件: 19, 20, 234, 326 |
30 |
Rhpth |
Parathyroid hormone |
D05364 |
2件: PTH1R, PTH2R |
3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action |
3件: 70, 235, 326 |
31 |
Rimiducid |
- |
- |
- |
- |
5件: 19, 65, 284, 285, 326 |
32 |
Stem cell transplantation |
- |
- |
- |
- |
9件: 13, 19, 20, 46, 65, 90, 164, 234, 326 |
33 |
Systemic chemotherapy and antibodies |
- |
- |
- |
- |
2件: 62, 326 |